NCT05901311View on ClinicalTrials.gov

A Study of [14C]-LY3537982 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

June 5, 2023

Primary Completion Date

August 10, 2023

Study Completion Date

August 10, 2023

Conditions

Healthy

Interventions

DRUG

LY3537982

Administered orally.

DRUG

[¹⁴C]-LY3537982

Administered orally.

DRUG

[¹⁴C]-LY3537982

Administered IV.

Trial Locations (1)

53704

Labcorp Clinical Research Unit Inc., Madison

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05901311 - A Study of [14C]-LY3537982 in Healthy Participants | Biotech Hunter | Biotech Hunter